IS8004A - Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn - Google Patents

Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn

Info

Publication number
IS8004A
IS8004A IS8004A IS8004A IS8004A IS 8004 A IS8004 A IS 8004A IS 8004 A IS8004 A IS 8004A IS 8004 A IS8004 A IS 8004A IS 8004 A IS8004 A IS 8004A
Authority
IS
Iceland
Prior art keywords
alzheimer
disease
prevention
delay
treatment
Prior art date
Application number
IS8004A
Other languages
English (en)
Inventor
Steven Shearman Mark
Turner Mervyn
Original Assignee
Merck Sharp & Dohme Limited
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Limited, Merck & Co., Inc. filed Critical Merck Sharp & Dohme Limited
Publication of IS8004A publication Critical patent/IS8004A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8004A 2003-03-14 2005-08-29 Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn IS8004A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45458903P 2003-03-14 2003-03-14
PCT/GB2004/000983 WO2004080459A1 (en) 2003-03-14 2004-03-08 Method for treating mild cognitive impairment and for preventing or delaying alzheimer’s disease

Publications (1)

Publication Number Publication Date
IS8004A true IS8004A (is) 2005-08-29

Family

ID=32990914

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8004A IS8004A (is) 2003-03-14 2005-08-29 Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn

Country Status (13)

Country Link
US (1) US20060241133A1 (is)
EP (1) EP1605940A1 (is)
JP (1) JP2006520371A (is)
KR (1) KR20050109990A (is)
CN (1) CN1794992A (is)
AU (1) AU2004218871A1 (is)
BR (1) BRPI0408295A (is)
CA (1) CA2518886A1 (is)
IS (1) IS8004A (is)
MX (1) MXPA05009850A (is)
NO (1) NO20054714L (is)
RU (1) RU2005131845A (is)
WO (1) WO2004080459A1 (is)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313772D0 (en) * 2003-06-13 2003-07-23 Merck Sharp & Dohme Therapeutic treatment
US7872009B2 (en) 2005-11-21 2011-01-18 Amgen Inc. Beta-Secretase modulators and methods of use
US7745484B2 (en) 2005-11-21 2010-06-29 Amgen Inc. Beta-secretase modulators and methods of use
CA2629402C (en) 2005-11-21 2011-07-26 Amgen Inc. Beta-secretase modulators and methods of use
US7838676B2 (en) * 2005-11-21 2010-11-23 Amgen Inc. Beta-secretase modulators and methods of use
TW200901991A (en) 2007-05-25 2009-01-16 Amgen Inc Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US8173810B2 (en) 2007-05-25 2012-05-08 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US7803809B2 (en) 2008-11-12 2010-09-28 Amgen Inc. Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use
PE20110805A1 (es) * 2008-09-11 2011-11-09 Amgen Inc Compuestos con anillos espiro-triciclicos como moduladores de beta-secretasas y metodos de uso
WO2011063272A1 (en) 2009-11-23 2011-05-26 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
US9296698B2 (en) 2009-11-23 2016-03-29 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
WO2011090911A1 (en) 2010-01-19 2011-07-28 Amgen Inc. Amino heteroaryl compounds as beta-secretase modulators and methods of use
ES2450568T3 (es) 2010-03-15 2014-03-25 Amgen Inc. Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
WO2011115938A1 (en) 2010-03-15 2011-09-22 Amgen Inc. Spiro-tetracyclic ring compounds as beta - secretase modulators
EP2673279A1 (en) 2011-02-07 2013-12-18 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta-secretase antagonists and methods of use
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
LU92126B1 (fr) * 2012-12-31 2014-07-01 Cesa Alliance Sa Composé pharmaceutique pour la prévention et le traitement d'un trouble ou d'une maladie de la mémoire, neurodégénérative ou neuronale

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902680A (en) * 1984-10-29 1990-02-20 Chaovanee Aroonsakul Treating central nervous system diseases
NZ258412A (en) * 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
WO1996033189A1 (en) * 1995-04-19 1996-10-24 Merck & Co., Inc. Process for the preparation of spiroindolines
US6028196A (en) * 1995-10-27 2000-02-22 Merck & Co., Inc. Process for the preparation of a growth hormone secretagogue
US5767124A (en) * 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
EP0900086A4 (en) * 1996-05-07 2000-01-12 Merck & Co Inc IMPROVING THE SLEEP BY MEANS OF A SUBSTANCE PROMOTING THE SECRETION OF GROWTH HORMONES
US6046333A (en) * 1996-10-25 2000-04-04 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
JP2002524402A (ja) * 1998-09-03 2002-08-06 ニューロンズ・リミテッド 神経保護
AU2405401A (en) * 1999-12-28 2001-07-09 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
EP1149583A3 (en) * 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues

Also Published As

Publication number Publication date
WO2004080459A1 (en) 2004-09-23
KR20050109990A (ko) 2005-11-22
US20060241133A1 (en) 2006-10-26
MXPA05009850A (es) 2005-12-06
NO20054714D0 (no) 2005-10-13
EP1605940A1 (en) 2005-12-21
BRPI0408295A (pt) 2006-03-07
CN1794992A (zh) 2006-06-28
AU2004218871A1 (en) 2004-09-23
RU2005131845A (ru) 2006-02-10
JP2006520371A (ja) 2006-09-07
CA2518886A1 (en) 2004-09-23
NO20054714L (no) 2005-11-16

Similar Documents

Publication Publication Date Title
IS8004A (is) Aðferð við meðhöndlun á vægri vitsmunaskerðingu og til að fyrirbyggja eða tefja Alzheimers-sjúkdóminn
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
EP1416961A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF A DISEASE
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
IS8071A (is) Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
EA200500098A1 (ru) Лекарственное средство и способ лечения патологического синдрома
NO20035609L (no) Fremgangsmate for kontinuerlig naftabehandling
DK1765388T3 (da) Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil
DE60305691D1 (de) Gusseisernes inneres Glied und Herstrellungsverfahren dafür
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
AU2003220096A8 (en) Methods for alzheimer's disease treatment and cognitive enhancement
AU2003246102A8 (en) Method of examining allergic disease and drug for treating the same
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
IS8497A (is) Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
NO20043085L (no) Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet
NO20053341D0 (no) Hindring og behandling av Alzheimers sykdom.
AU2003291536A8 (en) Method for the diagnosis and treatment of vascular disease
NO20054346D0 (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
EP1624786A4 (en) METHOD FOR THE TREATMENT AND PREVENTION OF ILLNESSES OF BIOLOGICAL CHANNELS
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
IS7136A (is) Aðferð til meðhöndlunar á svefnleysi á frumstigi